Incidental Head and Neck (18)F-FDG Uptake on PET/CT Without Corresponding Morphological Lesion: Early Predictor of Cancer Development?

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2009 Mar 24

PMID 19305995

Citations 9

Authors

Till A Heusner

Steffen Hahn

Monia E Hamami

Svenja Kogel

Michael Forsting

Andreas Bockisch

Gerald Antoch

Alexander R Stahl

Affiliations

Soon will be listed here.

Abstract

Purpose: To retrospectively determine whether increased/asymmetric FDG uptake on PET without a correlating morphological lesion on fully diagnostic CT indicates the development of a head and neck malignancy.

Methods: In 590 patients (mean age 55.4 +/- 13.3 years) without a head and neck malignancy/inflammation FDG uptake was measured at (a) Waldeyer's ring, (b) the oral floor, (c) the larynx, and (d) the thyroid gland, and rated as absent (group A), present (group B), symmetric (group B1) or asymmetric (group B2). Differences between groups A and B and between B1 and B2 were tested for significance with the U-test (p < 0.05). An average follow-up of about 2.5 years (mean 29.5 +/- 13.9 months) served as the reference period to determine whether patients developed a head and neck malignancy.

Results: Of the 590 patients, 235 (40%) showed no evidence of enhanced FDG uptake in any investigated site, and 355 (60%) showed qualitatively elevated FDG uptake in at least one site. FDG uptake values (SUV(max), mean+/-SD) for Waldeyer's ring were 3.0 +/- 0.89 in group A (n = 326), 4.5 +/- 2.18 in group B (n = 264; p < 0.01), 5.4 +/- 3.35 in group B1 (n = 177), and 4.1 +/- 1.7 in group B2 (n = 87; p < 0.01). Values for the oral floor were 2.8 +/- 0.74 in group A (n = 362), 4.7 +/- 2.55 in group B (n = 228; p < 0.01), 4.4 +/- 3.39 in group B1 (n = 130), and 5.1 +/- 2.69 in group B2 (n = 98, p = 0.01). Values for the larynx were 2.8 +/- 0.76 in group A (n = 353), 4.2 +/- 2.05 in group B (n = 237; p < 0.01), 4.0 +/- 2.02 in group B1 (n = 165), and 4.6 +/- 2.8 in group B2 (n = 72; p = 0.027). Values for the thyroid were 2.4 +/- 0.63 in group A (n = 404), 3.0 +/- 1.01 in group B (n = 186; p < 0.01), 2.6 +/- 0.39 in group B1 (n = 130), and 4.0 +/- 1.24 in group B2 (n = 56; p < 0.01). One patient developed a palatine tonsil carcinoma (group B1, SUV(max) 3.2), and one patient developed an oral floor carcinoma (group B1, SUV(max) 3.7).

Conclusion: Elevated/asymmetric head and neck FDG accumulation without a correlating morphological lesion can frequently be found and does not predict cancer development. In populations in which goitre is endemic, FDG uptake by the thyroid is common and not associated with thyroid cancer.

Citing Articles

Focal Nasopharyngeal Activity Detected on [F]FDG PET/CT: Clinical Implications and Comparison of Metabolic Parameters for Prediction of Malignancy.

Wong W Nucl Med Mol Imaging. 2022; 56(6):299-305.

PMID: 36425278 PMC: 9679055. DOI: 10.1007/s13139-022-00771-5.

Incidentalomas in the head & neck.

McQueen A, Al-Zuhir N, Ali T Br J Radiol. 2022; 96(1142):20220164.

PMID: 36317814 PMC: 9975523. DOI: 10.1259/bjr.20220164.

Carcinosarcoma of the colon with extensive and extraordinary metastases detected on F-FDG18PET/CT: A case report.

Maskrout M, Boutaggount F, Mokfi R, Ennibi G, Hnach Y, Tarchouli M Ann Med Surg (Lond). 2022; 81:104450.

PMID: 36147121 PMC: 9486715. DOI: 10.1016/j.amsu.2022.104450.

F-FDGPET/CT incidental detection of tumor-to-tumor metastasis in patients investigated for squamous cell lung cancer.

Rais G, Ziouziou I, Wakrim S, Serhane H Radiol Case Rep. 2022; 17(5):1450-1456.

PMID: 35265239 PMC: 8899109. DOI: 10.1016/j.radcr.2022.02.022.

Synchronous p16 nasopharyngeal and oropharyngeal squamous cell carcinoma: a case report and review.

Ali M, Kua H, Giddings C, Day D, McDowell L Clin Case Rep. 2021; 9(3):1350-1353.

PMID: 33768842 PMC: 7981711. DOI: 10.1002/ccr3.3765.

References

Antoch G, Kuehl H, Kanja J, Lauenstein T, Schneemann H, Hauth E . Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology. 2004; 230(3):879-85. DOI: 10.1148/radiol.2303021287. View

Stahl A, Stollfuss J, Ott K, Wieder H, Fink U, Schwaiger M . FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding. Nuklearmedizin. 2006; 44(6):249-55. View

Strauss L . Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996; 23(10):1409-15. DOI: 10.1007/BF01367602. View

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T . Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992; 33(11):1972-80. View

Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith S . PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics. 2004; 24(5):1411-31. DOI: 10.1148/rg.245035725. View

Schoder H, Yeung H, Gonen M, Kraus D, Larson S . Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004; 231(1):65-72. DOI: 10.1148/radiol.2311030271. View

Macapinlac H . FDG-PET in head and neck, and thyroid cancer. Chang Gung Med J. 2005; 28(5):284-95. View

Pfannenberg A, Aschoff P, Brechtel K, Muller M, Bares R, Paulsen F . Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006; 34(1):36-44. DOI: 10.1007/s00259-006-0186-3. View

Kamel E, Burger C, Buck A, von Schulthess G, Goerres G . Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scanner. Eur Radiol. 2003; 13(4):724-8. DOI: 10.1007/s00330-002-1564-2. View

10.

Blodgett T, Fukui M, Snyderman C, Branstetter 4th B, McCook B, Townsend D . Combined PET-CT in the head and neck: part 1. Physiologic, altered physiologic, and artifactual FDG uptake. Radiographics. 2005; 25(4):897-912. DOI: 10.1148/rg.254035156. View

11.

King D, Stack Jr B, Spring P, Walker R, Bodenner D . Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas. Otolaryngol Head Neck Surg. 2007; 137(3):400-4. DOI: 10.1016/j.otohns.2007.02.037. View

12.

Del Rocio Estrada-Sanchez G, Altamirano-Ley J, Ochoa-Carrillo F . [Normal variants and frequent pitfalls with (18)FDG PET/CT study]. Cir Cir. 2008; 75(6):491-7. View

13.

Ng S, Chan S, Yen T, Chang J, Liao C, Ko S . Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging. 2008; 36(1):12-22. DOI: 10.1007/s00259-008-0918-7. View

14.

Cook G, Fogelman I, Maisey M . Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996; 26(4):308-14. DOI: 10.1016/s0001-2998(96)80006-7. View

15.

Kapoor V, Fukui M, McCook B . Role of 18FFDG PET/CT in the treatment of head and neck cancers: posttherapy evaluation and pitfalls. AJR Am J Roentgenol. 2005; 184(2):589-97. DOI: 10.2214/ajr.184.2.01840589. View

16.

Rosenbaum S, Lind T, Antoch G, Bockisch A . False-positive FDG PET uptake--the role of PET/CT. Eur Radiol. 2005; 16(5):1054-65. DOI: 10.1007/s00330-005-0088-y. View

17.

Kawabe J, Okamura T, Shakudo M, Koyama K, Sakamoto H, Ohachi Y . Physiological FDG uptake in the palatine tonsils. Ann Nucl Med. 2001; 15(3):297-300. DOI: 10.1007/BF02987850. View

18.

Beyer T, Antoch G, Blodgett T, Freudenberg L, Akhurst T, Mueller S . Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging. 2003; 30(4):588-96. DOI: 10.1007/s00259-002-1097-6. View

19.

Babior B . The respiratory burst of phagocytes. J Clin Invest. 1984; 73(3):599-601. PMC: 425058. DOI: 10.1172/JCI111249. View

20.

Pentenero M, Cistaro A, Brusa M, Ferraris M, Pezzuto C, Carnino R . Accuracy of 18F-FDG-PET/CT for staging of oral squamous cell carcinoma. Head Neck. 2008; 30(11):1488-96. DOI: 10.1002/hed.20906. View